益肾化湿颗粒在糖尿病肾病患者sirt1通路的影响

摘要/Abstract

摘要： 目的探寻益肾化湿颗粒是否通过激活沉默信息调节因子1（sirt1）途径来对糖尿病肾病患者起到保护作用。方法选择2020年12月—2022年2月就诊于秦皇岛市第一医院的60例糖尿病肾病患者,按照随机数表法分为试验组与对照组,各30例。同时,选取秦皇岛市第一医院体检中心的20例体检者作为健康体检组。对照组给予基础治疗,试验组在基础治疗上服用益肾化湿颗粒,总疗程为3个月,比较两组患者治疗前后血清空腹血糖（FBG）、糖化血红蛋白（HbA_1c）、血肌酐（SCr）、尿酸（UA）、血尿素氮（BUN）、尿白蛋白排泄率（UAER）、肾小球滤过率估计值（eGFR）、β2微球蛋白（β2-MG）及sirt1水平。结果治疗前试验组与对照组FBG、HbA_1c、SCr、UA、BUN、UAER、eGFR、β2-MG、sirt1比较,差异无统计学意义（P>0.05）,有可比性,治疗后试验组较对照组SCr水平明显下降,差异有统计学意义（P<0.05）,其余各实验室指标组间比较,差异均无统计学意义（P>0.05）。糖尿病肾病患者血清sirt1水平明显低于健康体检组,差异有统计学意义（P<0.05）。结论 ①益肾化湿颗粒可以明显降低SCr值,从而改善肾功能。②sirt1可能作为糖尿病肾病的一种保护因子存在。③未能得出益肾化湿颗粒通过激活sirt1途径保护糖尿病肾病患者的有效结论。

关键词: 益肾化湿颗粒, 糖尿病肾病, 沉默信息调节因子1

Abstract: Objective To explore whether Yishenhuashi granules can protect diabetic nephropathy patients by activating sirt1 pathway. Methods 60 diabetic nephropathy patients admitted to Qinhuangdao First Hospital from December 2020 to February 2022 were randomly divided into experimental group and control group, with 30 patients in each group. At the same time, 20 cases of physical examination in physical examination Center of Qinhuangdao First Hospital were selected as the health examination group. The control group was given basic treatment, and the experimental group was given Yishenhuashi granule in addition to basic treatment. The total course of treatment was 3 months. Comparison of fasting blood glucose (FBG), glycosylated hemoglobin (HbA_1c), serum creatinine (Scr), uric acid (UA), blood urea nitrogen (BUN), urinary albumin excretion rate (UAER), estimated glomerular filtration rate (eGFR), β2 microglobulin (β2-MG) and silent information regulator 1(sirt1) level. Results There was no statistical difference between the healthy control group,The test group and the control group. Before treatment, there were no significant differences in FBG, HbA_1c, Scr, UA, BUN, UAER, eGFR, β2-MG and sirt1 between the experimental group and the control group (P>0.05). After treatment, Scr levels in the experimental group decreased significantly compared with the control group, with statistical significance (P<0.05). There was no statistical significance in other laboratory indexes between groups (P>0.05). SIRT1 level in diabetic nephropathy patients was significantly lower than that in health examination group, with statistical significance (P<0.05). Conclusion ①Yishenhuashi granules can significantly reduce Scr value and improve renal function. ②sirt1 may be a protective factor in diabetic nephropathy. ③It is not concluded that Yishenhuashi granules can protect diabetic nephropathy patients by activating sirt1 pathway.

Key words: yishenhuashi granules, diabetic nephropathy, silent information regulator 1

中图分类号:

R587.2

彭珊, 刘维萍, 邵雪, 张隆业, 郭永力, 管仁苹, 张彦芬, 刘海荣, 孙建丽, 苏娜, 魏鹍. 益肾化湿颗粒在糖尿病肾病患者sirt1通路的影响[J]. 中华养生保健, 2023, 41(18): 5-8.

PENG Shan, LIU Wei-ping, SHAO Xue, ZHANG Long-ye, GUO Yong-li, GUAN Ren-ping, ZHANG Yan-fen, LIU Hai-rong, SUN Jian-li, SU Na, WEI Kun. The Effect of Yishenhuashi Granules on SIRT1 Pathway in Diabetic Nephropathy Patients[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(18): 5-8.

参考文献

[1] 中华医学会内分泌学分会.中国成人糖尿病肾脏病临床诊断的专家共识[J].中华内分泌代谢杂志,2015,31(5):379-385.
[2] 罗进辉,张慧.益肾化湿颗粒联合氯沙坦钾片治疗慢性肾小球肾炎的临床观察[J].中国药房,2017,28(29):4123-4126.
[3] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华内分泌代谢杂志,2021,37(4):311-398.
[4] 中华中医药学会益肾化湿专家组.益肾化湿颗粒治疗肾脏病临床应用专家共识[J].中华肾病研究电子杂志,2020,9(3):97-101.
[5] PERSSON F, ROSSING P.Diagnosis of diabetic kidney disease: state of the art and future perspective[J]. Kidney International Supplements,2018,8(1):2-7.
[6] PARVING H H, HOMMEL E, MATHIESEN E, et al.Prevalence of microalbuminuria, arterial hypertension, retinopathy, and neuropathy in patients with insulin dependent diabetes[J]. Br Med J (Clin Res Ed),1988,296(6616):156-160.
[7] SAEEDI P, PETERSOHN I, SALPEA P, et al.Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas[J]. Diabetes research and clinical practice,2019,157:107843.
[8] ANG Y G, HENG B H, SAXENA N, et al.Annual all-cause mortality rate for patients with diabetic kidney disease in Singapore[J]. Journal of clinical & translational endocrinology,2016,4:1-6.
[9] AFKARIAN M, SACHS M C, KESTENBAUM B, et al.Kidney disease and increased mortality risk in type 2 diabetes[J]. Journal of the American Society of Nephrology,2013,24(2):302-308.
[10] REN H, SHAO Y, WU C, et al.Metformin alleviates oxidative stress and enhances autophagy in diabetic kidney disease via AMPK/SIRT1-FoxO1 pathway[J]. Molecular and cellular endocrinology,2020,500:110628.
[11] TANG B L.Sirt1 and the mitochondria[J]. Molecules and cells,2016,39(2):87.
[12] WEIR H J, YAO P, HUYNH F K, et al.Dietary restriction and AMPK increase lifespan via mitochondrial network and peroxisome remodeling[J].Cell metabolism,2017,26(6):884-896.
[13] HASEGAWA K, WAKINO S, YOSHIOKA K, et al.Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function[J]. Journal of Biological Chemistry, 2010,285(17):13045-13056.
[14] HASEGAWA K, WAKINO S, YOSHIOKA K, et al.Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression[J]. Biochemical and biophysical research communications,2008,372(1):51-56.
[15] KAUPPINEN A, SUURONEN T, OJALA J, et al.Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders[J]. Cellular signalling,2013,25(10):1939-1948.
[16] 梁亚林,张靖华,李斐,等.益肾化湿颗粒在早期糖尿病肾病中的应用观察[J].中医临床研究,2018,10(4):55-57.
[17] 尹秀英. 益肾化湿颗粒治疗糖尿病肾病早期蛋白尿的临床观察[J].中国中医药现代远程教育,2017,15(1):94-95.
[18] 李翠萍,王倩,顾叶文,等.益肾化湿颗粒治疗糖尿病肾病有效性与安全性的Meta分析[J].实用医学杂志,2020,36(5):682-688.